A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-3394
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children ; day:13 ; month:2 ; year:2020 ; pages:1-17
Health care analysis ; (13.2.2020), 1-17
- Urheber
-
Murano, Maria Cristina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10728-020-00390-1
- URN
-
urn:nbn:de:101:1-2020051120471361170907
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Murano, Maria Cristina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Stature
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
FDA
Cultures in bioethics
Problems of bioethics
Asian bioethics review
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Stature
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
FDA
Cultures in bioethics
Problems of bioethics
Asian bioethics review
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Stature
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
FDA
Cultures in bioethics
Problems of bioethics